ストックスクリーナーアプリを入手
1.33
0.38%
0.005
前日終値:
$1.325
開ける：
$1.27
24時間の取引高:
25,516
Relative Volume:
0.21
時価総額：
$3.54M
収益：
-
当期純損益:
$-9.32M
株価収益率:
-0.1046
EPS:
-12.7107
ネットキャッシュフロー:
$-7.30M
1週間 パフォーマンス:
-11.92%
1か月 パフォーマンス:
+20.91%
6か月 パフォーマンス:
-38.71%
1年 パフォーマンス:
-75.93%
1日の値動き範囲:
$1.2625
$1.3598
1週間の範囲:
$1.26
$1.5808
52週間の値動き範囲:
$0.952
$6.39
Tharimmune Inc Stock (THAR) Company Profile
THAR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
THAR
Tharimmune Inc
|
1.33 | 3.18M | 0 | -9.32M | -7.30M | -12.71 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Tharimmune Inc (THAR) 最新ニュース
Tharimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Tharimmune, Inc. SEC 10-Q Report - TradingView
Tharimmune appoints new executive chairman By Investing.com - Investing.com India
Tharimmune appoints new executive chairman - Investing.com Australia
Tharimmune IncAppoints Vincent Lopriore As Executive ChairmanSEC Filing - marketscreener.com
Tharimmune (THAR) Reports Promising Phase 1 Results for TH104 Bu - GuruFocus
Tharimmune (THAR) Advances TH104 as Key Medical Countermeasure | - GuruFocus
Tharimmune advances opioid prophylaxis drug TH104 - Investing.com
Tharimmune advances opioid prophylaxis drug TH104 By Investing.com - Investing.com South Africa
Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback - Corsicana Daily Sun
Tharimmune's New Drug Breakthrough: FDA Fast-Tracks Military Protection Against Weaponized Fentanyl - Stock Titan
Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors - Bluefield Daily Telegraph
Stocks of Tharimmune Inc (THAR) are poised to climb above their peers - Sete News
Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences - Jonesboro Sun
Breakthrough Drug TH104 Clinical Data Selected for Two Premier Medical Conferences DDW and EASL - Stock Titan
Tharimmune Appoints Clay Kahler And Gary Stetz To Board - citybiz
Tharimmune (THAR) Expands Board with New Appointments | THAR Sto - GuruFocus
Tharimmune expands board with two new directors By Investing.com - Investing.com India
Tharimmune expands board with two new directors - Investing.com
Tharimmune Adds $500M Success Story Entrepreneur and Financial Expert to Board Leadership - Stock Titan
Tharimmune Inc’s latest rating changes from various analysts - knoxdaily.com
Tharimmune Inc (THAR) Stock: Uncovering 52-Week Market Trends - investchronicle.com
These Numbers Show Just How Powerful Tharimmune Inc (NASDAQ: THAR) Stock Is - Stocksregister
Tharimmune expands board, appoints new directors By Investing.com - Investing.com Nigeria
Tharimmune expands board, appoints new directors - Investing.com
FDA Nods to Tharimmune’s Countermeasure for Opioid Threats By Investing.com - Investing.com South Africa
FDA Nods to Tharimmune’s Countermeasure for Opioid Threats - Investing.com Australia
Now Is The Time To Build A Position In Tharimmune Inc (NASDAQ:THAR) - Marketing Sentinel
Observations on the Tharimmune Inc (NASDAQ:THAR) Growth Curve - uspostnews.com
Tharimmune (THAR) Advances TH104 with FDA Feedback on New Drug A - GuruFocus
Tharimmune (THAR) Advances TH104 with FDA Feedback on New Drug Application | THAR Stock News - GuruFocus
Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback - The Joplin Globe
FDA Clears Path for Tharimmune's Military-Grade Fentanyl Defense Drug: No New Trials Needed - Stock Titan
Tharimmune announces board retirements ahead of annual meeting - Investing.com
Tharimmune announces board retirements ahead of annual meeting By Investing.com - Investing.com South Africa
Press Release Distribution & PR Platform - ACCESS Newswire
Tharimmune (THAR) Expands Board with New Appointment | THAR Stoc - GuruFocus
Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors - Chronicle-Tribune
Healthcare Investment Expert Managing $150M Portfolio Strengthens Tharimmune's Strategic Leadership - Stock Titan
Tharimmune reports data on new biparatopic biologics - BioWorld MedTech
THAR stock touches 52-week low at $1.12 amid sharp annual decline By Investing.com - Investing.com South Africa
THAR stock touches 52-week low at $1.12 amid sharp annual decline - Investing.com Australia
Tharimmune Reports Preclinical Data for Dual-Target Biologics - MarketScreener
Tharimmune Announces Positive Data With Novel Biparatopic PD-1/VEGF & Multispecific HER2/HER3 Biologics Leveraging Proprietary Epiclick(TM) Technology - MarketScreener
Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology - Weatherford Democrat
Breakthrough Cancer Drug Shows Superior Design: Tharimmune's Dual-Target Biologic Outperforms Competition - Stock Titan
Tharimmune receives Nasdaq non-compliance notice By Investing.com - Investing.com India
Tharimmune receives Nasdaq non-compliance notice - Investing.com Australia
Tharimmune Inc (THAR) 財務データ
収益
当期純利益
現金流量
EPS
Tharimmune Inc (THAR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| MILBY RANDY | CEO |
Dec 19 '24 |
Buy |
2.12 |
4,600 |
9,752 |
17,534 |
| Appajosyula Sireesh | Chief Operating Officer |
Nov 13 '24 |
Buy |
2.02 |
5,000 |
10,096 |
10,758 |
| MILBY RANDY | CEO |
Oct 08 '24 |
Buy |
2.09 |
2,500 |
5,221 |
12,934 |
| Appajosyula Sireesh | Chief Operating Officer |
Oct 08 '24 |
Buy |
1.93 |
5,000 |
9,650 |
16,364 |
1.54%
7.58%
大文字化:
|
ボリューム (24 時間):